Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Alkem Laboratories Ltd.

09 Feb 2019

5647.50

0.16%

Alkem Labs (3QFY19): Good business at a reasonable price. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Maintain BUY with a revised TP of Rs 2,340 (22x Dec-20E EPS). Alkems 3QFY19 performance was in line with our expectations. A softer acute season led to a 1% fall in the domestic business, while the 44% jump in the US helped in maintaining 10% plus YoY top line growth. Poor business mix (lower India sales) and increased raw material cost led to a ~680bps drop in gross margin. As a result, EBITDA margin shrunk 450bps YoY and EBITDA declined 13% to Rs 3.1bn. Reported PAT at Rs 2.1bn was up 14% YoY owing to higher taxes in 3QFY18

Number of FII/FPI investors increased from 551 to 589 in Sep 2025 qtr.

Alkem Laboratories Ltd.

05 Nov 2018

5647.50

0.16%

Alkem Labs (2QFY19): US drives growth. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Maintain BUY with a TP of Rs 2,415 (22x Sep'20E EPS). Alkems 2QFY19 performance was ahead of expectation with EBITDA margin improving 614bps QoQ to 19% (100bps beat) and PAT coming in at Rs 2.6bn, down 19%YoY (16% beat). Revenues grew 3%YoY to Rs 19bn, in line with our estimates. Within segments, India business declined 6%YoY on a high base due to post-GST restocking last year, while US revenues grew 55%YoY to Rs 4.7bn, on the back of new product launches and currency tailwinds.

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

03 Nov 2018, 03:19PM

5647.50

0.16%

Alkem Laboratories Ltd Q2FY19 results Comment

Results Update: Alkem Laboratories Ltd.

HDFC Securities

Alkem Laboratories Ltd Q2FY19 results Comment Revenue rose by 14.94% to Rs. 1918.92 Cr in Q2FY19 when compared to the previous quarter. Also, it rose by 3.22% when compared with Q2FY18.

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6600.0 on 14 Nov, 2025.

Alkem Laboratories Ltd.

02 Nov 2018

5647.50

0.16%

Strong show; outlook remains promising

Buy: Alkem Laboratories Ltd.

Motilal Oswal

2 November 2018 muted growth of 3%YoY to INR19.2b (v/s est. of INR17.5b) on back of 6% YoY decline in domestic formulation (DF, 69% of sales), which was off-set by strong 55% YoY growth in the US business (25% of sales). Gross margins declined by ~180bp YoY (flat QoQ) to ~60.2% due to increased share of relatively low margin US business. Increased other expenses and employee cost (up ~270bp and ~60bp, as percentage of sales) led to contraction of ~570bp YoY in EBITDA margin to 19% (our est. Sequentially, EBITDA margin has expanded ~610bp due to improved operating leverage. R&D; spend was INR1.1b, 5.5% of sales v/s 5.9% of sales in 1QFY19. PAT declined by ~21% YoY to INR2.

Number of FII/FPI investors increased from 551 to 589 in Sep 2025 qtr.

Alkem Laboratories Ltd.

14 Aug 2018

5647.50

0.16%

Alkem Labs - 1QFY19 Result Update

Buy: Alkem Laboratories Ltd.

Target

Reliance Securities

ff US FDA: Alkem is yet to receive The US FDA clearance for St. Louis facility. However, it has already received EIR for Daman unit (inspected in Mar'18), while the US FDA inspected its Baddi plant between 6-10th Aug-18 with zero observations....

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6600.0 on 14 Nov, 2025.

Alkem Laboratories Ltd.

11 Aug 2018

5647.50

0.16%

Alkem Labs (1QFY19): Growth stock. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Maintain BUY with a revised TP of Rs 2,410 (24x FY20E EPS) Alkems 1QFY19 results were largely below our estimates. Revenue at Rs 16.7bn, was up 28.9%YoY and 10.3%QoQ. EBITDA of Rs 2.1bn grew 127%YoY with margin coming up to 12.8%, up 550bps YoY. PAT at Rs 1.4bn was 115% higher than that in 1QFY18. The impressive growth is attributed to a low GST-hit base. EBITDA, margin, and PAT missed our estimates by 21%, 380bps, and 22% YoY respectively. Domestic growth was 25.7%.

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6600.0 on 14 Nov, 2025.

Alkem Laboratories Ltd.

31 May 2018

5647.50

0.16%

Alkem Labs (4QFY18): Weak quarter. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Maintain BUY with a revised TP of Rs 2,445 (24x FY20E EPS). The fourth quarter is seasonally weak for ALKEM, and 4QFY18 was no different. The top-line grew 21% YoY but declined 13%QoQ to Rs 15.1bn. EBITDA margin at 7.5% and PAT at Rs 745mn missed our estimates by ~440bps and 46% respectively. R&D; spend during the quarter was significant (7.4% of sales vs 6.7% expected), with 11 ANDAs filed in 4QFY18. There was also MTM loss of Rs 283mn included in other expenses for real estate investments. Adjusted for this, EBITDA margin was at 9.4% in 4QFY18.

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6600.0 on 14 Nov, 2025.

Alkem Laboratories Ltd.

15 Feb 2018

5647.50

0.16%

Result Update:Alkem Lab

Buy: Alkem Laboratories Ltd.

Target

Axis Direct

Strong gross margin of 64% (up 50 bps YoY/200 bps QoQ) and higher India (up 22% YoY) and US sales (up 17% QoQ) led to significant operating leverage, as EBITDA grew 34% YoY to Rs 3.6 bn (21% higher than our estimate).

Alkem Laboratories L.. has an average target of 5562.33 from 3 brokers.

Alkem Laboratories Ltd.

14 Feb 2018

5647.50

0.16%

Alkem Labs - 3QFY18 Result Update

Buy: Alkem Laboratories Ltd.

Reliance Securities

Robust Growth in India Business; Maintain BUY Alkem Laboratories (Alkem) has reported a healthy performance in 3QFY18. Its revenue grew by 17.4% YoY to Rs17.4bn on the back of robust 22% YoY and 13.7% YoY growth in India and other export business, respectively. Despite a soft 6.1% YoY growth (10% YoY in CC terms), its US business grew by 18.1% QoQ due to ramp-up in Benzonatate (owing to seasonality) and launch of gNexium/gPrasugrel. Led by positive operating leverage and low YoY base, EBITDA grew by 34.2% YoY to Rs3.6bn while EBITDA margin expanded by 258bps YoY to 20.7%. However, despite a strong operating performance, Alkem's adjusted PAT declined by 4.3% YoY due to...

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

12 Feb 2018

5647.50

0.16%

Alkem Labs (3QFY18): Strong quarter. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Maintain BUY with a revised TP of Rs 2,435 (25x Dec-19E EPS). Alkem Labs (ALKEM) followed up the bumper 2Q performance with another strong quarter in 3QFY18. Revenue came in at Rs 17.4bn, up 17% YoY, with the domestic business growing 15% YoY. EBITDA came in at 3.6bn, up 34% YoY. The margin was 20.7% (up ~250bps YoY), driven up largely by a strong gross margin and operating leverage. Improved gross margin (64%, +200bps QoQ) was largely owing to the product mix in India, with chronic contributing well in 3QFY18. However, mgt expects gross margin to moderate to sustainable levels of 60-62%. PAT came in at Rs 1.7bn, down 27% YoY, impacted by a higher tax rate (45.6% vs 7.5%). The one-off DTA adjustment after the change in the US tax laws was ~Rs 450mn.

ICICI Securities Limited increased Buy price target of Alkem Laboratories Ltd. to 6600.0 on 14 Nov, 2025.

Is Alkem Laboratories Ltd. worth buying?

140 Votes:

Buy 79.29%

Sell 14.29%

Hold 6.43%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf